New mpox strain identified in England
December 8, 2025
The detection of a new recombinant strain of mpox in England underscores the ongoing evolution of this virus and the global risks of continued circulation. This mixed strain, containing elements of clade Ib and clade IIb, was identified through genomic testing in a traveler returning from Asia. Health experts stress that vaccination remains the best defense, offering 75 to 80 percent protection. While the United Kingdom’s surveillance systems are robust, global inequities in vaccine access remain a major concern. As experts warn, unchecked viral spread increases the likelihood of recombination and adaptation, reinforcing mpox’s foothold as a persistent human pathogen.
A newly detected recombinant strain of mpox in England highlights the virus’s continuing evolution and the global implications of unchecked spread. Identified in a traveler returning from Asia, the new variant combines elements of clade Ib, which has shown signs of local transmission in Europe, and clade IIb, the strain responsible for the 2022 global outbreak. Although the virus currently remains unnamed, its emergence demonstrates what experts have long cautioned: ongoing mpox transmission allows the pathogen more opportunities to adapt and entrench itself in human populations.
The UK Health Security Agency (UKHSA) confirmed the case through genomic sequencing and emphasized that viral evolution is normal. However, the agency reiterated that vaccination remains the most effective protection against severe disease. The vaccine, which provides 75 to 80 percent efficacy, is recommended for high-risk groups such as individuals with multiple sexual partners, those engaging in group sex, or frequent visitors to sex-on-premises venues. Although no data yet exist on vaccine performance against this new strain, health officials anticipate a high level of cross-protection.
Experts have praised the United Kingdom’s early detection and strong infection control systems, but concerns persist for lower-resource settings. Professor Trudie Lang of the University of Oxford warned that in regions with limited surveillance and vaccine access, new recombinant strains could spread unchecked. Dr. Boghuma Titanji of Emory University added that continued viral circulation increases the likelihood of recombination and genetic adaptation, potentially making mpox a permanent human health threat.
With nearly 48,000 cases reported globally in 2025, including 2,500 in the past month, the emergence of this recombinant strain is a stark reminder of the need for sustained vigilance. Maintaining high vaccination coverage, expanding genomic surveillance, and ensuring equitable vaccine distribution will be critical to preventing mpox from becoming an entrenched global pathogen.